Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo treatments show promise for lymphedema in severe obesity

NCT ID NCT07520942

Symptom relief Sponsor: Applied Science Private University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adding TECAR therapy or shock wave therapy to standard treatment (complex decongestive therapy) could better reduce leg swelling in severely obese women with lymphedema. Forty-five women took part, receiving one of three treatments over four weeks. Researchers measured changes in leg size, pain, and quality of life at the start, after treatment, and at an 8-week follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Oct 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 18-75 years with bilateral lower limb lymphedema secondary to severe obesity (BMI ≥40 kg/m²) * Lymphedema duration of at least 3 months * Clinical diagnosis confirmed by an experienced lymphedema specialist with bilateral limb swelling (pitting or non-pitting edema extending above the ankle) * Ability to attend treatment sessions five times weekly for 4 weeks and follow-up assessments Exclusion Criteria: * Secondary lymphedema due to malignancy, radiation, surgery, or infection * Primary lymphedema * Acute deep vein thrombosis or history of recurrent thrombosis * Active infection or cellulitis * Peripheral arterial disease with ankle-brachial index below 0.8 * Uncontrolled cardiac failure or renal insufficiency * Pregnancy or lactation * Contraindications to ESWT or TECAR therapy including pacemaker or implanted electronic devices * Patients receiving concurrent lymphedema treatment or those who had received intensive treatment within the preceding 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphedema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lymphedema morbid obesity Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphedema Obesity / overweight

Contacts and locations

Locations

  • Modawah Physical Therapy Center

    Banī Suwayf, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.